LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 127 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $47,730 | -16.3% | 40,449 | 0.0% | 0.00% | – |
Q2 2023 | $57,033 | -6.0% | 40,449 | 0.0% | 0.00% | – |
Q1 2023 | $60,674 | +108246.4% | 40,449 | -16.5% | 0.00% | – |
Q4 2022 | $56 | -99.9% | 48,464 | 0.0% | 0.00% | – |
Q3 2022 | $55,000 | -46.6% | 48,464 | -25.6% | 0.00% | – |
Q2 2022 | $103,000 | -48.0% | 65,155 | -49.4% | 0.00% | – |
Q1 2022 | $198,000 | -37.1% | 128,683 | 0.0% | 0.00% | – |
Q4 2021 | $315,000 | -2.8% | 128,683 | 0.0% | 0.00% | – |
Q3 2021 | $324,000 | -11.7% | 128,683 | 0.0% | 0.00% | – |
Q2 2021 | $367,000 | +21.5% | 128,683 | 0.0% | 0.00% | – |
Q1 2021 | $302,000 | +37.9% | 128,683 | +3.5% | 0.00% | – |
Q4 2020 | $219,000 | +88.8% | 124,360 | 0.0% | 0.00% | – |
Q3 2020 | $116,000 | -8.7% | 124,360 | -14.9% | 0.00% | – |
Q2 2020 | $127,000 | +1.6% | 146,088 | -3.6% | 0.00% | – |
Q1 2020 | $125,000 | -7.4% | 151,487 | 0.0% | 0.00% | – |
Q4 2019 | $135,000 | -11.2% | 151,487 | -2.2% | 0.00% | – |
Q3 2019 | $152,000 | – | 154,850 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $39,477,000 | 3.01% |
Raffles Associates | 2,080,536 | $2,351,000 | 2.51% |
Defender Capital, LLC. | 5,184,035 | $5,862,000 | 2.30% |
Prescott General Partners LLC | 1,851,851 | $2,093,000 | 0.16% |
DAFNA Capital Management LLC | 140,000 | $158,000 | 0.04% |
Fort Sheridan Advisors LLC | 83,931 | $95,000 | 0.03% |
Long Focus Capital Management, LLC | 215,000 | $243,000 | 0.02% |
XTX Topco Ltd | 72,807 | $82,000 | 0.02% |
Ergoteles LLC | 490,895 | $555,000 | 0.02% |
Beirne Wealth Consulting Services, LLC | 45,000 | $51,000 | 0.02% |